Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous re-challenge with Plasmodium falciparum NF135.C10 in previously CPS-immunized volunteers
NL-OMON37778Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of Plasmodium falciparum sporozoites in malaria and Falciparum malaria (PF), sponsored by Radboud University Medical Center. Primary endpoint: Protective immunity against heterologous re-challenge. Started Aug 2012; status: active, not recruiting.
02
Drugs
Plasmodium falciparum sporozoites
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on NL-OMON37778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37778.